Pages

Friday, May 4, 2012

FDA Approves Everolimus For Kidney Tumors Caused By TSC.

Dow Jones Newswires Share to FacebookShare to Twitter (4/27, Dooren, Subscription Publication) reports that the Food and Drug Administration has approved the use of Novartis AG's Afinitor (everolimus) for the treatment of non-cancerous kidney tumors caused by a rare genetic disease called tuberous sclerosis complex (TSC) not requiring immediate surgery. Since 2009, the medication has been used in the US for treating kidney cancer when other medications fail. About 40,000 US patients reportedly suffer from the disease.
        Reuters Share to FacebookShare to Twitter (4/27) reports that everolimus is the first medication FDA has approved for treatment of these tumors.

No comments:

Post a Comment